GLEMONT CT5 CHEWABLE TABLETS 5MG

Ország: Malajzia

Nyelv: angol

Forrás: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Aktív összetevők:

MONTELUKAST SODIUM

Beszerezhető a:

Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd.

INN (nemzetközi neve):

MONTELUKAST SODIUM

db csomag:

30Tablet Tablets

Gyártó:

Glenmark Pharmaceuticals Limited

Betegtájékoztató

1
GLEMONT
Montelukast Sodium (chewable tablets 4mg & 5mg, tablets 10mg)
_Consumer Medication Information Leaflet (RiMUP) _
What is in this leaflet
1.
What Glemont is used for
2.
How Glemont works
3.
Before you use Glemont
4.
How to use Glemont
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of Glemont
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
What Glemont is used for
Glemont is used for:
-
Asthma, including preventing your
asthma symptoms during the day and
night. Glemont also prevents the
narrowing of airways triggered by
exercise.
-
Allergic rhinitis (seasonal and
perennial), including daytime and
nighttime symptoms: nasal congestion,
runny nose, nasal itching, and sneezing;
nasal congestion upon awakening,
difficulty going to sleep, and nighttime
awakenings; tearing, itchy, red, and
puffy eyes.
How Glemont works
Glemont a leukotriene receptor
antagonist that blocks substances called
leukotrienes. Leukotrienes cause
narrowing and swelling of airways in
your lungs. Blocking leukotrienes
improves asthma symptoms and helps
prevent asthma attacks. Leukotrienes
also cause allergy symptoms. Blocking
leukotrienes improves allergic rhinitis
(seasonal and perennial, also known as
outdoor and indoor nasal allergies).
Before you use Glemont
-
When you must not use it
Do not use this product if you are
allergic to any excipients of this
product.
-
Before you start to use it
Consult your doctor or pharmacist
before you start to use this product.
Use in children
For children 6 to 14 years old,
Glemont CT 5mg are available.
For children 2 to 5 years old, Glemont
CT 4mg are available.
Use in pregnancy
Women who are pregnant or intend to
become pregnant should consult their
doctor before taking Glemont.
Use in breast-feeding
It is not known if Glemont appears in
breast milk. You should consult your
doctor before taking Glemont if you
are breast-feeding or intend to breast-
feed.
-
Taking other medicines
In general, Glemont does not interfere
with other medicine

Termékjellemzők

30 mm
30 mm
32 mm
_For the use only of a Registered Medical Practitioner or a Hospital
or a laboratory_
COMPOSITION
Each uncoated tablet contains:
Montelukast sodium equivalent to 4 mg Montelukast
Also includes mannitol and aspartame equivalent to 0.674 mg of
phenylalanine.
DESCRIPTION
Oval, white to off white coloured, biconvex uncoated tablets engraved
with “G” on one side
and “390” on other side.
GLEMONT CT5
(MONTELUKAST CHEWABLE TABLETS 5MG)
COMPOSITION
Each uncoated tablet contains:
Montelukast sodium equivalent to 5 mg Montelukast
Also includes mannitol and aspartame equivalent to 0.842 mg of
phenylalanine.
DESCRIPTION
Round, white to off white coloured, biconvex uncoated tablets engraved
with “G” on one side
and “391” on other side.
PHARMACOLOGY
Pharmacodynamic
_Mechanism of Action_
The cysteinyl leukotrienes (LTC 4, LTD 4, LTE 4) are products of
arachidonic acid metabolism
and are released from various cells, including mast cells and
eosinophils. These eicosanoids
bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1
(CysLT1) receptor is found
in the human airway (including airway smooth muscle cells and airway
macrophages) and on
other pro- inflammatory cells (including eosinophils and certain
myeloid stem cells). CysLTs
have been correlated with the pathophysiology of asthma and allergic
rhinitis. In asthma,
leukotriene mediated effects include airway edema, smooth muscle
contraction, and altered
cellular activity associated with the inflammatory process. In
allergic rhinitis, CysLTs are
released from the nasal mucosa after allergen exposure during both
early- late-phase
reactions and are associated with symptoms of allergic rhinitis.
Intranasal challenge with
CysLTs has been shown to increase nasal airway resistance and symptoms
of nasal
obstruction. Montelukast has not been assessed in intranasal challenge
studies. The clinical
relevance of intranasal challenge studies is unknown.
Montelukast is an orally active compound that binds with high affinity
and selectivity to the